Lataa...
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific...
Tallennettuna:
| Julkaisussa: | Antiviral Res |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier B.V.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7219369/ https://ncbi.nlm.nih.gov/pubmed/32405117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2020.104820 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|